Investigadores de la USC identifican compuestos que atacan la inflamación cerebral del alzhéimer

Español

Científicos de la Universidad del Sur de California han hallado compuestos experimentales que podrían reducir la inflamación cerebral dañina asociada con la enfermedad de Alzheimer. El trabajo se centra en la enzima cPLA2 y en las personas portadoras del gen de alto riesgo APOE4.

Investigadores de la Universidad del Sur de California identificaron compuestos que inhiben selectivamente la cPLA2, una enzima vinculada a la inflamación en el cerebro. Los hallazgos fueron publicados en la revista npj Drug Discovery en 2026. El equipo relacionó una mayor actividad de la cPLA2 con un mayor riesgo de alzhéimer entre los portadores del gen APOE4, aunque la enzima también contribuye al funcionamiento normal del cerebro.

Artículos relacionados

Microscopic illustration of protective microglia clearing amyloid plaques in an Alzheimer's brain model due to the OLE molecule
Imagen generada por IA

Study identifies OLE molecule that shifts microglia into a more protective state in Alzheimer’s models

Reportado por IA Imagen generada por IA Verificado por hechos

Researchers in Spain and Switzerland report that an experimental molecule called OLE helped restore protective behavior in the brain’s immune cells in animal models of Alzheimer’s disease, reducing amyloid-related pathology and improving performance on memory and movement tests.

Indiana university team targets idol enzyme to treat alzheimer's

Researchers at the Indiana University School of Medicine have identified the enzyme IDOL as a potential new target for treating Alzheimer's disease. Laboratory studies showed that removing the enzyme from neurons reduced amyloid plaques and improved brain cell communication.

Large genetic study uncovers new Alzheimer’s drug targets

Reportado por IA

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

Health

Nanoparticles reduced amyloid-β and improved cognition in an Alzheimer’s mouse model, researchers report

Health

Study links APOE2 variant to stronger DNA repair and reduced cellular aging in human neurons

Health

Copper compound restores memory in Alzheimer’s lab tests

University of Kentucky study links microglia to sleep loss in Alzheimer’s-model mice

Researchers at the University of Kentucky report that overactive microglia—immune cells in the brain—can drive sleep loss in mice with amyloid plaques. In the study, temporarily depleting most microglia restored more than two hours of sleep per day, even though plaque levels did not change.

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

Reportado por IA

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

21 de julio de 2026 10:04

Japan scientists identify clusters of protein believed to trigger Alzheimer’s disease

20 de julio de 2026 22:16

SORLA protein found to shield brain from Alzheimer’s tau damage

17 de julio de 2026 05:39

Experimental drug reduced DNA damage and inflammation in an Alzheimer’s mouse model, King’s College London says

19 de junio de 2026 07:18

UC Riverside study proposes new Alzheimer's trigger

30 de abril de 2026 12:13

Scientists restore memory in Alzheimer's mice by blocking PTP1B

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar